Sanofi Blocks Launch Of Dr. Reddy's Generic Allegra-D 24 Hour; 20 Suits Are Pending Over Other Formulations
Executive Summary
Over the past decade Sanofi-Aventis has filed more than 20 suits seeking to ward off generic competition for its Allegra franchise. It won a major victory on June 14 when a court granted a preliminary injunction to prevent Dr. Reddy's from launching a generic version of Allegra-D 24 Hour (fexofenadine 180 mg/pseudoephedrine 240 mg)
You may also be interested in...
Perrigo Gains Pole Position In Private-Label Allegra Race
Perrigo cuts to the front of the queue for launching private-label versions of OTC Allegra, acquiring from Teva the exclusive U.S. sales and distribution rights to generic equivalents of the allergy drug
Perrigo Gains Pole Position In Private-Label Allegra Race
Perrigo cuts to the front of the queue for launching private-label versions of OTC Allegra, acquiring from Teva the exclusive U.S. sales and distribution rights to generic equivalents of the allergy drug
Sanofi-Aventis Will Enter U.S. OTC Market By Paying $1.9 Billion For Chattem
The deal, which is Sanofi's latest attempt to diversity in the face of a looming patent cliff, provides a platform for Rx-to-OTC switches.